# US 2022/0033767 A1 · Armored cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0033767 A1
- Document ID: US20220033767A1
- Status: Published application
- Kind: A1
- Application number: 17/277,260
- Filed: 2019-09-24
- Published: 2022-02-03
- Earliest claimed: 2018-09-24
- Inventors: Jimin Guo; C. Jeffrey Brinker; Wei Zhu
- Web page: https://patentgrep.com/patent/US20220033767A1

## CPC

- C12N 5/0006: {Modification of the membrane of cells, e.g. cell decoration}
- A61K 47/6901: {Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors}
- C12N 5/0641: {Erythrocytes}
- C12N 5/0647: {Haematopoietic stem cells; Uncommitted or multipotent progenitors}
- B82Y 5/00: Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
- C12N 2500/22: Zinc; Zn chelators
- C12N 2500/24: Iron; Fe chelators; Transferrin
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- B82Y: SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES

## Abstract

A modified vertebrate cell comprising a vertebrate cell encased in reversibly interlinked metal-organic framework (MOF) nanoparticles, and methods of making and using the modified cell, are provided.

## Claims

### Claim 1

A modified vertebrate cell comprising a vertebrate cell encased in reversibly interlinked metal-organic framework (MOF) nanoparticles.

### Claim 2 (depends on 1)

The modified cell of claim 1 which is a mammalian cell.

### Claim 3 (depends on 2)

The modified cell of claim 2 which is a human cell.

### Claim 4 (depends on 1)

The modified cell of claim 1 which is a non-adherent cell.

### Claim 5 (depends on 1)

The modified cell of claim 1 which is a red blood cell.

### Claim 6 (depends on 1)

The modified cell of claim 1 which is a hematopoietic cell.

### Claim 7

(canceled)

### Claim 8 (depends on 1)

The modified cell of claim 1 wherein the MOF nanoparticles comprise ZIF-8, MIL-100(Fe), UiO-66-NH2, magnetic iron oxide (Fe3O4) NPs@ZIF-8, or mesoporous silica NP@ZIF-8, or a combination thereof.

### Claim 9 (depends on 1)

The modified cell of claim 1 wherein the nanoparticles have a diameter of about 100 am to about 500 nm, about 100 nm to about 200 nm or about 400 nm to about 500 nm.

### Claim at position 10

10-11. (canceled)

### Claim 12 (depends on 1)

The modified cell of claim 1 wherein the nanoparticles further comprise a covalently attached moiety which optionally is a cell targeting moiety, an optically detectable molecule, a diagnostic molecule or a therapeutic molecule.

### Claim 13

(canceled)

### Claim 14 (depends on 1)

The modified cell of claim 1 wherein the mesopores in the nanoparticles further comprise a molecule which is optionally an optically detectable molecule, a diagnostic molecule or a therapeutic molecule.

### Claim at position 14

15-20. (canceled)

### Claim 21

A method of making vertebrate cells encased in reversibly interlinked metal-organic framework nanoparticles, comprising:
providing a population of vertebrate cells, a population of MOF nanoparticles and a ligand; and
adding the MOF nanoparticles and ligand to the cells under conditions that allow for interconnecting the MOF nanoparticles via the ligand.

### Claim 22 (depends on 21)

The method of claim 21 wherein the MOF nanoparticles have a negative charge ranging from −3.0 to −30 mV in 0.2× PBS.

### Claim 23 (depends on 21)

The method of claim 21 wherein the ligand comprises tannic acid, epigallocatechin gallate, epicatechin gallate myricetin, quercetin, quercetagetin, eupafolin, luteolin, scutellarein, dicaffeoylquinic, theaflavin, heaflavin-3′-gallate (TF1), theaflavin-3, 3′-digallate (TF2) or a combination thereof.

### Claim 24 (depends on 21)

The method of claim 21 wherein the MOF nanoparticles are in an acidic isotonic buffer that alters the zeta potential of the MOF nanoparticles.

### Claim 25 (depends on 24)

The method of claim 24 wherein the buffer ranges from pH 5 to pH 7.

### Claim 26 (depends on 21)

The method of claim 21 wherein the cells are red blood cells.

### Claim 27 (depends on 21)

The method of claim 21 wherein the MOF nanoparticles comprise ZIF-8, MIL-100(Fe), UiO-66, UiO-66-NH2, magnetic iron oxide (Fe3O4) NPs@ZIF-8, or mesoporous silica NP@ZIF-8, or a combination thereof.

### Claim at position 22

28-30. (canceled)

### Claim 31 (depends on 21)

The method of claim 21 wherein the nanoparticles further comprise a covalently attached moiety.

### Claim 32

(canceled)

### Claim 33 (depends on 21)

The method of claim 21 wherein the mesopores in the nanoparticles further comprise a molecule.

### Claim at position 26

34-35. (canceled)

### Claim 36

A method to disrupt linkages in vertebrate cells encased in reversibly interlinked metal-organic framework (MOF) nanoparticles, comprising:
contacting a population of vertebrate cells encased in reversibly interlinked metal-organic framework nanoparticles with an agent that disrupts the linkages.

### Claim 37

(canceled)